Prophase Labs Stock Performance
| PRPH Stock | USD 0.26 0.05 23.81% |
The company holds a Beta of -3.44, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ProPhase Labs are expected to decrease by larger amounts. On the other hand, during market turmoil, ProPhase Labs is expected to outperform it. At this point, ProPhase Labs has a negative expected return of -3.72%. Please make sure to check ProPhase Labs' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if ProPhase Labs performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ProPhase Labs has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:10 | Dividend Date 2022-06-03 | Ex Dividend Date 2022-05-24 | Last Split Date 2025-12-22 |
1 | How strong is ProPhase Labs Inc. stock revenue growth - July 2025 Rallies Long-Term Investment Growth Plans - newser.com | 11/10/2025 |
2 | ProPhase Labs in MA discussions not connected to crypto treasury strategy PRPH | 11/19/2025 |
3 | ProPhase Labs, Inc. Q3 2025 Earnings Call Transcript | 11/20/2025 |
4 | Acquisition by Ted Karkus of 500000 shares of ProPhase Labs at 0.6 subject to Rule 16b-3 | 11/21/2025 |
5 | Prophase Labs Secures Forbearance Agreement with Avtech Capital - TipRanks | 11/25/2025 |
6 | Prophase Labs Faces Unsealed Civil Action Disclosure - MSN | 12/15/2025 |
7 | 12 Health Care Stocks Moving In Fridays Pre-Market Session | 01/02/2026 |
8 | ProPhase Labs Updates Shareholders Amid Volatility and OTC Move - TipRanks | 01/09/2026 |
9 | ProPhase Labs Uplists from Pink Sheets to OTC Market | 01/22/2026 |
| Begin Period Cash Flow | 1.6 M | |
| Total Cashflows From Investing Activities | 2.4 M |
ProPhase Labs Relative Risk vs. Return Landscape
If you would invest 377.00 in ProPhase Labs on October 29, 2025 and sell it today you would lose (351.00) from holding ProPhase Labs or give up 93.1% of portfolio value over 90 days. ProPhase Labs is currently does not generate positive expected returns and assumes 11.6274% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than ProPhase, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ProPhase Labs Target Price Odds to finish over Current Price
The tendency of ProPhase Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.26 | 90 days | 0.26 | about 86.18 |
Based on a normal probability distribution, the odds of ProPhase Labs to move above the current price in 90 days from now is about 86.18 (This ProPhase Labs probability density function shows the probability of ProPhase Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days ProPhase Labs has a beta of -3.44 indicating as returns on its benchmark rise, returns on holding ProPhase Labs are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, ProPhase Labs is expected to outperform its benchmark. Additionally ProPhase Labs has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. ProPhase Labs Price Density |
| Price |
Predictive Modules for ProPhase Labs
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ProPhase Labs. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ProPhase Labs Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ProPhase Labs is not an exception. The market had few large corrections towards the ProPhase Labs' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ProPhase Labs, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ProPhase Labs within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -3.6 | |
β | Beta against Dow Jones | -3.44 | |
σ | Overall volatility | 1.36 | |
Ir | Information ratio | -0.34 |
ProPhase Labs Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ProPhase Labs for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ProPhase Labs can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ProPhase Labs generated a negative expected return over the last 90 days | |
| ProPhase Labs has high historical volatility and very poor performance | |
| ProPhase Labs has some characteristics of a very speculative penny stock | |
| ProPhase Labs has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.77 M. Net Loss for the year was (49.52 M) with profit before overhead, payroll, taxes, and interest of 987 K. | |
| ProPhase Labs currently holds about 27.5 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from globenewswire.com: ProPhase Labs Uplists from Pink Sheets to OTC Market |
ProPhase Labs Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ProPhase Stock often depends not only on the future outlook of the current and potential ProPhase Labs' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ProPhase Labs' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.9 M | |
| Cash And Short Term Investments | 678 K |
ProPhase Labs Fundamentals Growth
ProPhase Stock prices reflect investors' perceptions of the future prospects and financial health of ProPhase Labs, and ProPhase Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProPhase Stock performance.
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (5.40) % | ||||
| Current Valuation | 8.36 M | ||||
| Shares Outstanding | 4.19 M | ||||
| Price To Earning | 6.59 X | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 0.16 X | ||||
| Revenue | 6.77 M | ||||
| Gross Profit | 987 K | ||||
| EBITDA | (32.34 M) | ||||
| Net Income | (49.52 M) | ||||
| Cash And Equivalents | 27.5 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 24.57 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 1.65 X | ||||
| Cash Flow From Operations | (17.54 M) | ||||
| Earnings Per Share | (19.80) X | ||||
| Market Capitalization | 795.7 K | ||||
| Total Asset | 63.2 M | ||||
| Retained Earnings | (58.39 M) | ||||
| Working Capital | (1.5 M) | ||||
| Current Asset | 9.73 M | ||||
| Current Liabilities | 6.25 M | ||||
About ProPhase Labs Performance
By evaluating ProPhase Labs' fundamental ratios, stakeholders can gain valuable insights into ProPhase Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ProPhase Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ProPhase Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 69.33 | 131.75 | |
| Return On Tangible Assets | (1.27) | (1.21) | |
| Return On Capital Employed | (1.43) | (1.36) | |
| Return On Assets | (0.97) | (0.92) | |
| Return On Equity | (8.35) | (7.93) |
Things to note about ProPhase Labs performance evaluation
Checking the ongoing alerts about ProPhase Labs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProPhase Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProPhase Labs generated a negative expected return over the last 90 days | |
| ProPhase Labs has high historical volatility and very poor performance | |
| ProPhase Labs has some characteristics of a very speculative penny stock | |
| ProPhase Labs has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.77 M. Net Loss for the year was (49.52 M) with profit before overhead, payroll, taxes, and interest of 987 K. | |
| ProPhase Labs currently holds about 27.5 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from globenewswire.com: ProPhase Labs Uplists from Pink Sheets to OTC Market |
- Analyzing ProPhase Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProPhase Labs' stock is overvalued or undervalued compared to its peers.
- Examining ProPhase Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProPhase Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProPhase Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProPhase Labs' stock. These opinions can provide insight into ProPhase Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |